136 related articles for article (PubMed ID: 38318778)
1. A Spontaneous Assembling Lipopeptide Nanoconjugate Transporting the Anthracycline Drug
Sabnis N; Raut S; Nagarajan B; Kapic A; Dossou AS; Lothstein L; Fudala R; Bunnell BA; Lacko AG
Bioconjug Chem; 2024 Feb; 35(2):187-202. PubMed ID: 38318778
[TBL] [Abstract][Full Text] [Related]
2. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
Rathore K; Cekanova M
Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
[TBL] [Abstract][Full Text] [Related]
3. N-benzyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumours: cellular pharmacology and characterisation of cross-resistance in vitro and in vivo.
Ganapathi R; Grabowski D; Sweatman TW; Seshadri R; Israel M
Br J Cancer; 1989 Dec; 60(6):819-26. PubMed ID: 2605093
[TBL] [Abstract][Full Text] [Related]
4. Activity of N-benzyl-adriamycin-14-valerate (AD198), a new anthracycline derivate, in multidrug resistant human ovarian and breast carcinoma cell lines.
Harstrick A; Vanhoefer U; Schleucher N; Schroeder J; Baumgart J; Scheulen ME; Wilke H; Seeber S
Anticancer Drugs; 1995 Oct; 6(5):681-5. PubMed ID: 8845478
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
6. N-benzyladriamycin-14-valerate (AD198) induces apoptosis through protein kinase C-delta-induced phosphorylation of phospholipid scramblase 3.
He Y; Liu J; Durrant D; Yang HS; Sweatman T; Lothstein L; Lee RM
Cancer Res; 2005 Nov; 65(21):10016-23. PubMed ID: 16267027
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma.
Moussa E; Zamzam M; Kamel A; Salah Z; Attia I; Gaber L; Soliman R; Ezzat S
J Egypt Natl Canc Inst; 2017 Mar; 29(1):53-56. PubMed ID: 28258912
[TBL] [Abstract][Full Text] [Related]
8. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
9. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.
Smolensky D; Rathore K; Cekanova M
BMC Cancer; 2015 Nov; 15():927. PubMed ID: 26597249
[TBL] [Abstract][Full Text] [Related]
10. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
Lothstein L; Hosey LM; Sweatman TW; Koseki Y; Dockter M; Priebe W
Oncol Res; 1993; 5(6-7):229-34. PubMed ID: 7907237
[TBL] [Abstract][Full Text] [Related]
11. CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma.
Flores G; Everett JH; Boguslawski EA; Oswald BM; Madaj ZB; Beddows I; Dikalov S; Adams M; Klumpp-Thomas CA; Kitchen-Goosen SM; Martin SE; Caplen NJ; Helman LJ; Grohar PJ
Mol Cancer Ther; 2020 May; 19(5):1183-1196. PubMed ID: 32127464
[TBL] [Abstract][Full Text] [Related]
12. CD99 triggering in Ewing sarcoma delivers a lethal signal through p53 pathway reactivation and cooperates with doxorubicin.
Guerzoni C; Fiori V; Terracciano M; Manara MC; Moricoli D; Pasello M; Sciandra M; Nicoletti G; Gellini M; Dominici S; Chiodoni C; Fornasari PM; Lollini PL; Colombo MP; Picci P; Cianfriglia M; Magnani M; Scotlandi K
Clin Cancer Res; 2015 Jan; 21(1):146-56. PubMed ID: 25501132
[TBL] [Abstract][Full Text] [Related]
13. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
14. A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript.
Grohar PJ; Glod J; Peer CJ; Sissung TM; Arnaldez FI; Long L; Figg WD; Whitcomb P; Helman LJ; Widemann BC
Cancer Chemother Pharmacol; 2017 Sep; 80(3):645-652. PubMed ID: 28735378
[TBL] [Abstract][Full Text] [Related]
15. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
[TBL] [Abstract][Full Text] [Related]
16. In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma.
Dos Santos MP; de Farias CB; Roesler R; Brunetto AL; Abujamra AL
Oncol Rep; 2014 Feb; 31(2):955-68. PubMed ID: 24316794
[TBL] [Abstract][Full Text] [Related]
17. Protection from doxorubicin-induced cardiomyopathy using the modified anthracycline N-benzyladriamycin-14-valerate (AD 198).
Cai C; Lothstein L; Morrison RR; Hofmann PA
J Pharmacol Exp Ther; 2010 Oct; 335(1):223-30. PubMed ID: 20668052
[TBL] [Abstract][Full Text] [Related]
18. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
19. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma.
Stegmaier K; Wong JS; Ross KN; Chow KT; Peck D; Wright RD; Lessnick SL; Kung AL; Golub TR
PLoS Med; 2007 Apr; 4(4):e122. PubMed ID: 17425403
[TBL] [Abstract][Full Text] [Related]
20. Imatinib inhibits proliferation of Ewing tumor cells mediated by the stem cell factor/KIT receptor pathway, and sensitizes cells to vincristine and doxorubicin-induced apoptosis.
González I; Andreu EJ; Panizo A; Inogés S; Fontalba A; Fernández-Luna JL; Gaboli M; Sierrasesúmaga L; Martín-Algarra S; Pardo J; Prósper F; de Alava E
Clin Cancer Res; 2004 Jan; 10(2):751-61. PubMed ID: 14760098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
